Literature DB >> 679097

Calcium infusion and pentagastrin injection in diagnosis of medullary thyroid carcinoma.

M Verdy, J P Cholette, J Cantin, A Lacroix, W C Sturtridge.   

Abstract

Calcium infusion and pentagastrin injection were compared as tests to stimulate calcitonin secretion for the detection of medullary carcinoma of the thyroid. Plasma concentrations of immunoreactive calcitonin were measured by radioimmunoassay before and during both stimulation tests in 2 persons who had been found at operation to have medullary thyroid carcinoma, 1 relative in whom a cervical lymph node biopsy had shown medullary thyroid carcinoma and 36 asymptomatic relatives. The tests were carried out on separate days by intravenous infusion of calcium gluconate for 2 hours, to provide 3.75 mg/kg of elemental calcium per hour, and rapid intravenous injection of 0.5 microgram/kg of pentagastrin. Before stimulation immunoreactive calcitonin was undetectable in the plasma of 34 of the 36 asymptomatic persons; the 2 with elevated baseline concentrations of the hormone had a positive response to both tests. Seven others showed an increase in plasma immunoreactive calcitonin concentration only after pentagastrin injection. The two persons with initially elevated values and three of the seven with increased values after pentagastrin injection were found at subsequent operation to have focal medullary carcinoma and parafollicular cell hyperplasia; after the operation immunoreactive calcitonin was undetectable in the plasma, even after stimulation. Rapid injection of pentagastrin is more reliable than slow infusion of calcium as a stimulation test for the early detection of medullary thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 679097      PMCID: PMC1818282     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  15 in total

1.  Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity.

Authors:  J B HAZARD; W A HAWK; G CRILE
Journal:  J Clin Endocrinol Metab       Date:  1959-01       Impact factor: 5.958

2.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

3.  C-cell hyperplasia preceding medullary thyroid carcinoma.

Authors:  H J Wolfe; K E Melvin; S J Cervi-Skinner; A A Saadi; J F Juliar; C E Jackson; A H Tashjian
Journal:  N Engl J Med       Date:  1973-08-30       Impact factor: 91.245

4.  Separation of antibody-bound and unbound peptide hormones labelled with iodine-131 by talcum powder and precipitated silica.

Authors:  G Rosselin; R Assan; R S Yalow; S A Berson
Journal:  Nature       Date:  1966-10-22       Impact factor: 49.962

5.  A short calcium infusion in the diagnosis of medullary thyroid carcinoma.

Authors:  J G Parthemore; D Bronzert; G Roberts; L J Deftos
Journal:  J Clin Endocrinol Metab       Date:  1974-07       Impact factor: 5.958

6.  Radioimmunoassay for calcitonin in medullary thyroid carcinoma.

Authors:  L J Deftos
Journal:  JAMA       Date:  1974-01-28       Impact factor: 56.272

7.  Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay.

Authors:  K E Melvin; H H Miller; A H Tashjian
Journal:  N Engl J Med       Date:  1971-11       Impact factor: 91.245

8.  Immunoassay for human calcitonin. I. Method.

Authors:  L J Deftos
Journal:  Metabolism       Date:  1971-12       Impact factor: 8.694

9.  Comparison of serum calcitonin levels after a 1-minute calcium injection and after pentagastrin injection in the diagnosis of medullary thyroid carcinoma.

Authors:  R K Rude; F R Singer
Journal:  J Clin Endocrinol Metab       Date:  1977-05       Impact factor: 5.958

10.  Immunoassay for human calcitonin. II. Clinical studies.

Authors:  L J Deftos; A E Bury; J F Habener; F R Singer; J T Potts
Journal:  Metabolism       Date:  1971-12       Impact factor: 8.694

View more
  7 in total

Review 1.  Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls.

Authors:  Giuseppe Costante; Cosimo Durante; Zélia Francis; Martin Schlumberger; Sebastiano Filetti
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-01

Review 2.  Calcitonin as a biomarker of C cell disease: recent achievements and current challenges.

Authors:  Giuseppe Costante; Domenico Meringolo
Journal:  Endocrine       Date:  2020-01-10       Impact factor: 3.633

3.  Screening for familial medullary thyroid carcinoma: a review.

Authors:  B A Ponder
Journal:  J R Soc Med       Date:  1984-07       Impact factor: 5.344

4.  The calcitonin levels can sometimes mislead parathyroid surgeons in patients with chronic kidney disease and renal hyperparathyroidism: report of a case.

Authors:  Ralph Schneider; Johanna E Schaumburg; Detlef K Bartsch; Katja Schlosser
Journal:  Surg Today       Date:  2013-04       Impact factor: 2.549

5.  Stimulated calcitonin cut-offs by different tests.

Authors:  Laura Fugazzola
Journal:  Eur Thyroid J       Date:  2013-01-16

6.  Multiple endocrine neoplasia, type II: a combined surgical and genetic approach to treatment.

Authors:  M W Partington; W R Ghent; E V Sears; N E Simpson
Journal:  Can Med Assoc J       Date:  1981-02-15       Impact factor: 8.262

Review 7.  The spectrum of thyroid diseases in childhood and its evolution during transition to adulthood: natural history, diagnosis, differential diagnosis and management.

Authors:  C A Koch; N J Sarlis
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 5.467

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.